MYC and Mobius syndrome: For example, Group 3 MB generally carry a poor prognosis, particularly MYC amplified cases which are often refractory to conventional therapy [41,42,43], while Group 4 MBs demonstrate a variable prognosis, incorporating favorable-risk MBs harboring chromosome 11 loss or chromosome 17 gain [14].